15.05.2013 - Funding agencies from 13 European countries have kicked off a €15.5m initiative for synthetic biology.
The funding call is the first one of the ERA-Net SynBio, a network of 16 national funding agencies that kicked off in 2012 and wants to boost cross-border collaborations in synthetic biology. Funding topics will range from metabolic engineering for sustainable chemistry over regulatory circuits to provide new functions in cells and organisms to so-called orthogonal biosystems, which express genes and proteins with completely new functions. Furthermore the funding will go into components for cell-based machines or cell-free devices to perform complex new tasks, microorganisms with minimal genomes, and synthetic protocells.
Each proposal must involve a minimum of three partners from at least three different European funding countries. Consortia involving US-partners must involve partners from a minimum of four countries.
ERASynBio, which launched last year, also seeks to stimulate collaborations between academia and industry and integrate them into focused research projects, and by providing training opportunities and creating an interdisciplinary advisory board.
"Synthetic biology has the potential to address some of the major challenges of the 21st century as well as offering innovations to benefit the economy“, said BBSRC Chief Executive Douglas Kell. „By applying engineering principles to biological research we have the potential to shape the future of industrial compounds, biofuels and new medicines, and to provide exciting insights into fundamental biological mechanisms."
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more